Skip to main content
SpringerLink
Log in

Multimodale Therapieansätze beim Hochrisikoprostatakarzinom – was wann?

Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Murthy V, Maitre P, Kannan S et al (2021) Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial. J Clin Oncol 39(11):1234–1242. https://doi.org/10.1200/JCO.20.03282

    Article  CAS  PubMed  Google Scholar 

  2. Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal boost to the Intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://doi.org/10.1200/JCO.20.02873

    Article  CAS  PubMed  Google Scholar 

  3. Attard G, Murphy L, Clarke NW et al (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 399(10323):447–460. https://doi.org/10.1016/S0140-6736(21)02437-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Xie W, Regan M, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Berry D, Clarke N, Collette L, D’Amico A, Lourenco R, Dignam J, Eisenberger M, James N, Fizazi K, Gillessen S, Loriot Y, Mottet N, Parulekar W, Sandler H, Spratt D, Sydes M, Tombal B, Williams S, Sweeney C (2020) Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol 38(26):3032–3041

    Article  Google Scholar 

  5. Xie W, Regan M, Buyse M, Halabi S, Kantoff P, Sartor O, Soule H, Clarke N, Collette L, Dignam J, Fizazi K, Paruleker W, Sandler H, Sydes M, Tombal B, Williams S, Sweeney C (2017) Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 35(27):3097–3104

    Article  CAS  Google Scholar 

  6. Valle L, Lehrer E, Markovic D, Elashoff D, Levin-Epstein R, Karnes R, Reiter R, Rettig M, Calais J, Nickols N, Dess R, Spratt D, Steinberg M, Nguyen P, Davis B, Zaorsky N, Kishan A (2021) A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur Urol 80(3):280–292

    Article  Google Scholar 

  7. Cagney DN, Dunne M, O’Shea C et al (2017) Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy. BMC Urol 17:60. https://doi.org/10.1186/s12894-017-0250-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nguyen PL, Huang HC, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko J, Pollack A, Dicker AP, Roach M, Rosenthal SA, Morginstin M, Mendez L, Hartford AC, Hall WA, Desai AB, Rabinovitch R, Peters CA, Rodgers J, Feng FY (2021) Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 111(3 Suppl):S50. https://doi.org/10.1016/j.ijrobp.2021.07.133

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Inselspital, Bern University, Freiburgstr. 10, 3010, Bern, Schweiz

    Etienne Mathier,  Astrid Heusel &  Mohamed Shelan

Authors
  1. Etienne Mathier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Astrid Heusel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mohamed Shelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Shelan.

Ethics declarations

Interessenkonflikt

E. Mathier, A. Heusel und M. Shelan geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mathier, E., Heusel, A. & Shelan, M. Multimodale Therapieansätze beim Hochrisikoprostatakarzinom – was wann?. Strahlenther Onkol 198, 962–965 (2022). https://doi.org/10.1007/s00066-022-01968-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-01968-5

Search

Navigation